Open Nav

ZeClinics SL

  • Davide D'Amico, ZeClinics

Opening a Series A round for pre-clinical development

  • Date:Wednesday, October 17
  • Time:10:45 AM - 11:00 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:ZePharma is the drug discovery branch of ZeClinics. ZePharma and the older ZeClinics Contract Research Organization branch are focused on the use of zebrafish for drug discovery and development. ZePharma has significantly shortened the time took to discover new therapeutic molecules, by utilizing ZeCardio, a zebrafish-based innovative high-throughput screening platform, developed by ZeClinics under the most prestigious grant program from the European Commission, SME Instrument Phase 2. The company is currently developing those molecules in CRISPR-edited pre-clinical models for unmet cardiovascular needs. Implying zebrafish in early R&D steps, allows ZePharma to screen thousands of other molecules in a short space of time and gain in depth understanding of how each molecular structure will target disease. With such business model ZePharma will be continuously fed with new molecular entities to move on drug development and final out-licensing to big pharmaceutical corporations.
  • Company
  • Company HQ City:Barcelona
  • Company HQ Country:Spain
  • CEO/Top Company Official:Davide D'Amico
  • Year Founded:2013
  • Main Therapeutic Focus:Cardiovascular
  • Lead Product in Development :Small Molecules
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :4
  • Additional Information/Comments:ZePharma core business is the discovery & development of new drugs in the most demanding indications of the cardiovascular biomedical sector. It is divided into three business units, each with its own research goals, but all commonly started in zebrafish and by applying high throughput screening and “humanized” disease models generated with CRISPR genome editing technology: - CardioProtection: this pipeline is dedicated to the discovery of drugs to assist in the prevention and treatment of cardiovascular toxic phenomena, mainly caused by common chemotherapeutics drugs used in oncology. - Cardiomyopathies: a platform to identify, validate and develop new molecules targeting novel pathways against genetic forms of cardiomyopathies. - CardioRegeneration: in this unit new molecular targets are discovered and validated for their role in regeneration of cardiac tissues upon injuries and a target-based strategy is used for the discovery of molecules acting on this process.
  • Previous and Current Investors:Business angels, public grants
  • Size of Last Investment Round:€1.8m
  • Total Amount Raised to Date, In All Rounds:€2.9m
Davide D'Amico